Legend Biotech Corp is a leading biopharmaceutical company that values innovation, integrity, and a patient-centric approach. With a strong corporate philosophy focused on advancing novel cell therapies, Legend Biotech Corp strives to improve the lives of patients around the world. The company is committed to developing cutting-edge treatments for oncology and autoimmune diseases, utilizing its expertise in gene and cell therapies. With a dedication to scientific excellence and a patient-first mindset, Legend Biotech Corp continues to push the boundaries of medical innovation and deliver transformative therapies to those in need.

Legend Biotech Corp is primarily present in multiple countries and regions. With its headquarters in Somerset, New Jersey, the company has an extensive global presence. It operates in key markets such as the United States, China, and Europe. Legend Biotech Corp has established strategic collaborations and partnerships to extend its reach and leverage market opportunities. By expanding its operations internationally, the company aims to capitalize on the diverse healthcare landscapes and maximize its potential for growth and innovation.

Legend Biotech Corp has achieved several significant milestones in its trajectory. Notably, the company successfully completed a Phase 1b/2 clinical trial for its lead product candidate, LCAR-B38M CAR-T cell therapy. This innovative therapy demonstrated compelling clinical responses in patients with relapsed or refractory multiple myeloma, leading to breakthrough status designation by the U.S. FDA. Subsequently, Legend Biotech Corp went on to initiate a global Phase 2 pivotal trial for LCAR-B38M. These achievements showcase the company's dedication to advancing groundbreaking treatments for patients, solidifying its position as a frontrunner in the biotech industry.

Legend Biotech Corp is a renowned biopharmaceutical company that focuses on developing cutting-edge cell therapies for patients with cancer. Founded in 2015 and headquartered in Somerset, New Jersey, Legend Biotech Corp is an affiliate of Genscript Biotech Corporation. The company primarily specializes in CAR-T cell therapies and has established a strong global presence. With a strong emphasis on research and development, Legend Biotech Corp has collaborated with numerous academic institutions and industry experts to advance the field of cell therapy. Leveraging its expertise and innovative approach, the company strives to improve the lives of patients worldwide by providing novel and effective treatments for various types of cancer.

The main competitors of Legend Biotech Corp in the market include prominent biotechnology companies such as Gilead Sciences, Inc., Celgene Corporation, and bluebird bio, Inc.

Legend Biotech Corp is primarily active in the field of biotechnology.

Legend Biotech Corp is a leading biopharmaceutical company that specializes in the discovery and development of innovative cell therapies. The company's business model revolves around leveraging its cutting-edge technologies and expertise in genetic engineering to develop personalized and off-the-shelf cell therapies for the treatment of various forms of cancer. By harnessing the power of the immune system, Legend Biotech aims to revolutionize the field of oncology and improve patient outcomes. With a focus on research and development, collaborations, and strategic partnerships, Legend Biotech is dedicated to advancing the future of cell-based immunotherapy and transforming the way cancer is treated.

P/E odnos Legend Biotech iznosi -38,23.

KUV kompanije Legend Biotech iznosi 25,63.

AlleAktien kvalitativni skor za Legend Biotech je 4/10.

očekivana Legend Biotech promet je 598,91 mil. USD.

Dobit očekivana Legend Biotech je -401,48 mil. USD.

Legend Biotech Corp is an innovative biotechnology company specializing in the development of cell therapies for cancer and autoimmune diseases. The company was founded in 2015 and is headquartered in Somerset, New Jersey. Its business model focuses on discovering and developing therapies for difficult-to-treat diseases, utilizing expertise in gene and cell therapy as well as a proprietary platform for designing, manufacturing, and optimizing therapy products. The company has two main divisions: cancer therapy and autoimmune therapy. In cancer therapy, Legend Biotech Corp focuses on developing immunotherapies that activate the body's immune system to destroy cancer cells, with a promising pipeline of cell therapies for various types of cancer. In autoimmune therapy, the company is developing cell therapies for diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, using a similar approach to the cancer therapy division. The company's product portfolio includes several products in various stages of clinical development, including CAR-T cell therapies for the treatment of Hodgkin's lymphoma and multiple myeloma. Legend Biotech Corp also places a strong emphasis on partnerships and collaborations, working closely with research institutions, universities, and other biotechnology companies to optimize its technology and therapy platforms and develop new products. Overall, the company's business model is characterized by innovative research and development, a focus on discovering new therapies, and close collaboration with partners and other industry stakeholders. The company is well positioned to develop and bring successful cell therapies for cancer and autoimmune diseases to the market.

Legend Biotech isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Legend Biotech trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Legend Biotech je US52490G1022.

WKN od Legend Biotech je A2P5AH.

Oznaka za praćenje akcija kompanije Legend Biotech je LEGN.

U poslednjih 12 meseci, Legend Biotech je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Legend Biotech će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Legend Biotech trenutno iznosi .

Legend Biotech isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Legend Biotech je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Legend Biotech se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Legend Biotech od 5. 11. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 5. 11. 2024..

Isplata poslednje dividende izvršena je 5. 11. 2024..

U godini 2023 kompanija Legend Biotech je isplatila 0 USD kao dividende.

Dividende od Legend Biotech se isplaćuju u USD.